---

ANTI-VEGF - Key Points by Slide

---

Slide 3 - VEGF Overview

• VEGF = family of dimeric glycoproteins that act as master regulators of angiogenesis (new blood vessel formation) and vascular permeability
• Initially called "vascular permeability factor" (VPF) by Dvorak in 1983, independently identified as VEGF by Ferrara and colleagues in 1989
• Upregulated primarily by tissue hypoxia; act on endothelial cells to promote vessel growth, survival, migration, and leakage

---

Slide 4 - The VEGF Family

---

Slide 5 - Isoforms of VEGF-A

• VEGF-A165: Most abundant and biologically potent; binds VEGFR-1, VEGFR-2 and heparan sulfate proteoglycans. This is the primary therapeutic target.
• VEGF-A121: Freely diffusible; less potent
• VEGF-A189: Tightly ECM-bound; least diffusible

---

Slide 6 - VEGF Receptors

• VEGF receptors are receptor tyrosine kinases (RTKs)
• VEGFR-1 (Flt-1), VEGFR-2 (KDR/Flk-1) — key receptors for clinical disease
• VEGFR-2 is the primary signaling receptor driving pathological angiogenesis

---

Slide 7 - The Angiopoietin-Tie Axis

• Ang-1: Produced by pericytes → activates Tie2 → promotes vascular stability, reduces permeability
• Ang-2: Acts as competitive antagonist of Ang-1 — destabilizes vessels, sensitizes them to VEGF-driven sprouting
• VEGF-A and Ang-2 are synergistic: Ang-2 destabilizes the vessel wall, VEGF drives sprouting
• Blocking only VEGF-A leaves Ang-2-driven permeability unchecked — this is the rationale for faricimab's dual blockade

---

Slide 8 - VEGF in Normal Retinal Physiology

• Nasal retina vascularized by 8 months gestation; temporal periphery by ~1 month after birth — VEGF is the primary driver
• Low-level constitutive VEGF from RPE maintains fenestrated choriocapillaris
• Loss of trophic VEGF may contribute to geographic atrophy — potential unintended consequence of long-term anti-VEGF

---

Slide 9 - Neuroprotection

• VEGF has direct neuroprotective effects on retinal ganglion cells and photoreceptors via VEGFR-2 signaling
• In ROP: excessive VEGF suppression may impair retinal neurodevelopment
• Anti-VEGF rapidly regresses iris neovessels (NVI) in neovascular glaucoma

---

Slide 10 - The Hypoxia Cascade ⭐

Most important pathway to memorize:

---

Slide 11 - Disease-Specific Triggers

---

Slide 12 - Rationale for Intravitreal Delivery

• Intravitreal injection (IVI) achieves:
  • Micromolar drug concentrations (orders of magnitude above VEGF IC50)
  • Minimal systemic exposure vs IV administration
  • Bypasses the blood-retinal barrier (BRB) entirely
• Elimination: anteriorly via trabecular meshwork; across BRB into systemic circulation

---

Slide 13 - Structural Comparison ⭐

---

Slide 14 - Doses & Approvals ⭐

---

Slide 15 - Pharmacokinetics ⭐

---

Slide 16 - Dosing Regimens ⭐

---

Slide 17 - Contraindications

• Active periocular or intraocular infection
• Active severe intraocular inflammation (uveitis)
• Known hypersensitivity

• Pregnancy — use intravitreal triamcinolone instead
• Recent stroke or MI within 3 months (especially bevacizumab — systemic VEGF suppression)
• Mature fibrotic disciform scar (treatment futile — no active VEGF-driven disease)

---

Slide 18 - Safety Profile ⭐

---

Slide 19 - Safety (Systemic)

• Systemic ATEC (stroke/MI): Not significantly increased with any intravitreal agent
• Pregnancy: Avoid all anti-VEGF — bevacizumab has highest systemic VEGF suppression
• ROP neonates: Ranibizumab preferred (fastest systemic clearance, no Fc)
• Biosimilars available: SB11, FYB201 (ranibizumab); ABP 938 (aflibercept 2mg)

---

Slide 20 - Suboptimal Response / Tachyphylaxis

• Tachyphylaxis = progressively decreasing response to repeated anti-VEGF
• Primary non-response: Persistent exudation despite ≥3 injections → disease not primarily VEGF-driven
• Secondary (acquired) resistance: Initial response → declining efficacy over months-years
• Pseudo-tachyphylaxis: Apparent resistance due to undertreatment / missed injections

---

Slide 21 - Clinical Indicators of Suboptimal Response

• Persistent SRF and/or IRF on OCT despite ≥3 properly-timed injections
• Failure to extend TAE beyond 4–6 weeks despite multiple attempts
• Declining VA despite anatomical stability
• Progressive geographic atrophy despite treatment

---

Slide 22 - Mechanisms of Resistance

• Anti-drug antibodies (ADA): Neutralizing antibodies reduce free drug availability
• VEGF-C/D escape pathway: Persistent exudation driven by VEGF-C/D (not targeted by standard agents; targeted by OPT-302)
• PDGF-B upregulation: Drives neovascularization independently of VEGF-A → rationale for 4D-150 dual gene therapy
• Fibrotic remodeling: Longstanding CNV becomes less VEGF-dependent
• Persistent Ang-2 activity: Residual vascular instability → rationale for switching to faricimab

---

Slide 23 - Switching Strategy ⭐

• Switch after ≥3 injections with persistent exudation
• Switch to Faricimab first — adds Ang-2 blockade (mechanism untouched by VEGF-A monotherapy)
• Switch to Aflibercept 8mg — higher molar dose overcomes partial concentration-dependent resistance
• Switch to intravitreal steroid (DME): when inflammatory/non-VEGF mechanisms dominate

---

Slides 25–28 - nAMD Clinical Trials ⭐

---

Slides 30–32 - DME Clinical Trials ⭐

---

Slide 34 - PDR Trials ⭐

---

Slides 36–37 - RVO Trials ⭐

---

Slide 39 - ROP Trials ⭐

---

Slide 41 - Recent Advances ⭐

---

Slide 42 - Gene Therapy Pipeline

---

Slide 43 - Emerging Targets Beyond VEGF-A

---

Slide 46 - Choosing an Initial Agent ⭐

---

Slide 47 - Monitoring Protocol

• Monthly OCT during loading phase and first 3 months
• VA + OCT at every visit — both guide treatment decisions
• IOP measurement at every anti-VEGF visit
• FFA/ICG: not needed at every visit; for initial diagnosis or unexplained OCT changes
• OCT-A: increasingly used to visualize CNV activity without dye injection

---

Slide 49 - Take-Home Messages ⭐⭐

1. VEGF-A acting via VEGFR-2 is the primary molecular target in all major neovascular/exudative retinal diseases
2. HIF-1α is the master upstream regulator — hypoxia → HIF-1α → VEGF → pathological vessels
3. Ang-2 is the key co-conspirator — faricimab's dual VEGF-A/Ang-2 blockade is the most significant mechanistic advance since anti-VEGF began
4. Start treatment within 2–3 weeks of symptom onset; better baseline VA = better final VA
5. Faricimab (q16w max) and Aflibercept 8mg (q12–16w) offer the longest intervals currently available
6. Brolucizumab achieves long intervals but carries higher risk of vision-threatening IOI
7. Biosimilars (SB11, ABP 938) are clinically equivalent to originators and expanding global access

---

Legend: Items in bold are the most important facts, numbers, and concepts you should prioritize when studying. Tables with ⭐ are the highest-yield slides to memorize.

---

🎓 ANTI-VEGF — Complete Study Guide + Presentation Coaching

---

SLIDE 3 — What is VEGF?

🧠 Understand It First (Simple Language)

• Vascular = related to blood vessels
• Endothelial = the cells lining blood vessels
• Growth Factor = a protein that tells cells to grow/multiply

1. Grows new blood vessels (angiogenesis)
2. Makes existing vessels leaky (vascular permeability)

• 1983 — Dvorak called it "Vascular Permeability Factor (VPF)" — he noticed it made vessels leaky
• 1989 — Ferrara renamed it VEGF after realizing it also grows vessels

🧠 Memory trick: "Dvorak = 1983, Ferrara = 1989" → D before F, 3 before 9

---

🎤 How to Present Slide 3

"Before we talk about anti-VEGF drugs, we need to understand what VEGF actually is and why it's so dangerous in the eye."

"VEGF is essentially the body's emergency signal to build new blood vessels. It was first discovered by Dvorak in 1983 as a 'vascular permeability factor' — meaning it made vessels leaky. Then in 1989, Ferrara identified it as a growth factor too. In the eye, this dual action — leakage AND abnormal vessel growth — is exactly what destroys vision in diseases like AMD and DME."

"So when we block VEGF, we're turning off both the leakage and the vessel growth at the same time."

---

---

SLIDE 4 — The VEGF Family

🧠 Understand It First

• Most drugs (ranibizumab, bevacizumab, brolucizumab) only block VEGF-A
• Aflibercept is smarter — it also blocks VEGF-B and PlGF
• Faricimab doesn't block PlGF but adds Ang-2 blockade (completely different mechanism)

🧠 Memory trick for PlGF: "PlGF = Pathological loop amplifier" — it kicks in when disease is already bad and makes VEGF-A even worse. Aflibercept cuts both.

---

🎤 How to Present Slide 4

"VEGF-A is the main criminal in retinal disease — it drives neovascularization and vascular leakage in AMD, DME, RVO, PDR, and ROP. But it has accomplices."

"VEGF-B and PlGF are targeted by aflibercept — giving it a broader blockade than ranibizumab or bevacizumab. PlGF is particularly important because it amplifies VEGF-A in ischemic and diabetic conditions — exactly when you need stronger suppression."

"VEGF-C and D are emerging escape mechanisms — patients who stop responding to standard anti-VEGF may be driven by VEGF-C, which is why OPT-302 is in trials."

"Everything we're going to discuss today is aimed primarily at this one molecule."

---

---

SLIDE 5 — Isoforms of VEGF-A

🧠 Understand It First

1. It's the most abundant form in the eye
2. It's the most potent driver of disease
3. It binds both VEGFR-1 and VEGFR-2

🧠 Memory trick: 165 = "1 drug target, 65% of your focus" — it's the one that matters most.

---

🎤 How to Present Slide 5

"VEGF-A exists in multiple isoforms — essentially different-sized versions of the same protein. The one we care about most is VEGF-A165. It's the most abundant, the most biologically active, and it's the primary therapeutic target for all the drugs we'll discuss."

"The differences between isoforms relate to how far they can travel — 165 strikes the right balance between potency and diffusibility."

---

---

SLIDE 6 — VEGF Receptors

🧠 Understand It First

🧠 Memory trick: "R-2 is what you want to block — think RTK-2 = Retinal Trouble Kinase 2" (made up, but helps you remember VEGFR-2 is the bad one)

---

🎤 How to Present Slide 6

"VEGF works by binding to receptors on endothelial cells — and there are three, but VEGFR-2 is the one that matters. When VEGF-A binds VEGFR-2, it activates a tyrosine kinase cascade that tells the cell: proliferate, migrate, and open your tight junctions. That's the signal we need to block."

"VEGFR-1 actually acts partly as a decoy receptor — it mops up excess VEGF without strong signaling. VEGFR-3 is mostly about lymphatics and is less relevant in retinal disease."

---

---

SLIDE 7 — The Angiopoietin-Tie Axis

🧠 Understand It First

• Ang-1 = the security guard who keeps vessels stable and tight
• Ang-2 = the saboteur who fires the security guard, leaving vessels vulnerable

• Ang-1 (from pericytes) → binds Tie2 → vessel is stable, not leaky ✅

• Ang-2 (released from endothelial cells) → competes with Ang-1 → blocks Tie2 → vessel becomes unstable and leaky ❌
• Then VEGF swoops in and grows new abnormal vessels on top of that ❌❌

When you only block VEGF-A, Ang-2 is still active and still destabilizing vessels. That's why some patients don't respond fully to standard anti-VEGF.

🧠 Memory trick: "Ang-2 = Anarchy-2 — it creates chaos in the vessel wall, letting VEGF do its damage"

---

🎤 How to Present Slide 7

"Now here's a mechanism that most people don't know — and it explains why faricimab is a step forward."

"There's a parallel system called the Angiopoietin-Tie axis. Ang-1, produced by pericytes, keeps blood vessels stable. Ang-2, stored in endothelial cells, does the opposite — it destabilizes vessels and makes them sensitive to VEGF. In AMD and DME, Ang-2 is upregulated."

"The problem with blocking only VEGF-A is that Ang-2 is still active, still destabilizing the vessel wall. Faricimab solves this by blocking both. This is the first genuinely new mechanism in retinal treatment in over a decade."

---

---

SLIDE 8 & 9 — VEGF in Normal Physiology

🧠 Understand It First

1. Why we can't block VEGF too aggressively, especially in babies (ROP)
2. Why long-term anti-VEGF may cause geographic atrophy (dry AMD)

🧠 Memory trick for ROP: "Oxygen is given to premature babies → suppresses VEGF → vessels stop growing → when oxygen stops, VEGF surges → disease." It's a 2-phase problem.

---

🎤 How to Present Slides 8 & 9

"Before we move to pathology, it's important to recognize that VEGF is not purely an enemy — the body needs it. Low-level VEGF from the RPE maintains the choriocapillaris. VEGF also protects photoreceptors and ganglion cells. This is why over-suppression is a real concern."

"In premature babies, giving oxygen is lifesaving but suppresses VEGF — vessels stop growing. When oxygen is eventually reduced, VEGF surges uncontrollably. That's ROP. So anti-VEGF in ROP is potent but must be used carefully."

"Long-term, we worry that suppressing all VEGF might starve the choriocapillaris, potentially accelerating geographic atrophy in AMD patients. An area of active research."

---

---

SLIDE 10 — The Hypoxia Cascade ⭐⭐⭐

🧠 Understand It First — THIS IS THE MOST IMPORTANT SLIDE

🔴 Step 1: Tissue runs low on oxygen (hypoxia) — from diabetes, vessel blockage, RPE stress, etc.

🟠 Step 2: A protein called HIF-1α (Hypoxia Inducible Factor-1 alpha) normally gets destroyed constantly. But when there's no oxygen, it survives and accumulates (stabilization).

🟡 Step 3: HIF-1α travels to the nucleus of the cell and attaches to specific DNA sequences called HREs (Hypoxia Response Elements) — like inserting a key into a lock.

🟢 Step 4: This turns ON the VEGF-A gene → the cell starts making and secreting VEGF-A protein.

🔵 Step 5: VEGF-A binds VEGFR-2 on nearby retinal and choroidal endothelial cells.

🟣 Step 6: Endothelial cells start proliferating AND their tight junctions break down (leakage).

⚫ Step 7: Pathological new vessels grow (CNV, NVE, NVD) AND fluid leaks → SRF, IRF, hard exudates form.

💀 Step 8: Fluid damages photoreceptors → visual loss.

🧠 Memory trick — use the acronym HHVELD:

• Hypoxia
• HIF-1α stabilizes
• VEGF gene activated
• Endothelial proliferation + leakage
• Lesion forms (SRF/IRF/CNV)
• Damage to photoreceptors = vision loss

---

🎤 How to Present Slide 10

"This is the central cascade — understand this and you understand why every drug we use works the way it does."

"It all starts with hypoxia. When a tissue is starved of oxygen — whether from a blocked retinal vein, diabetic capillary loss, or RPE stress — a protein called HIF-1α accumulates. Normally it's constantly degraded, but without oxygen, it survives."

"HIF-1α then goes to the cell nucleus and turns on the VEGF-A gene. VEGF-A is secreted, finds VEGFR-2 on the endothelial cells of retinal blood vessels, and gives two orders: proliferate, and open your tight junctions. The result is new leaky vessels and fluid accumulation in the retina — and that fluid directly damages photoreceptors."

"Every anti-VEGF drug acts at one point in this chain: blocking VEGF-A before it reaches VEGFR-2. Simple concept, massive impact."

---

---

SLIDE 11 — Disease-Specific Triggers

🧠 Understand It First

🧠 Memory trick: "Müller cells = the Main VEGF Makers" (3 M's)

---

🎤 How to Present Slide 11

"The same VEGF pathway is triggered across all these diseases — the difference is just what triggers it. In AMD, it's RPE aging and oxidative stress. In diabetes, it's pericyte loss and advanced glycation end-products causing ischemia. In RVO, it's the backed-up venous pressure causing retinal hypoxia. In ROP, it's a two-phase process — oxygen suppresses VEGF first, then a surge follows."

"Importantly, Müller cells are the common final pathway — they sense retinal stress and pump out VEGF in almost every condition."

---

---

SLIDE 12 — Why Intravitreal Injection?

🧠 Understand It First

1. Micromolar drug concentrations right at the target — far above the VEGF IC50 (the dose needed to inhibit VEGF by 50%)
2. Minimal systemic exposure — almost none gets into the bloodstream
3. Bypasses the BRB entirely — you're already inside the eye

• Anteriorly: drains through the trabecular meshwork with aqueous humor
• Posteriorly: crosses the BRB into systemic circulation (rate depends on molecular weight and Fc region)

🧠 Key fact for safety: Drugs with Fc regions (bevacizumab, aflibercept, faricimab) can undergo FcRn-mediated transcytosis across the BRB → more systemic exposure. Ranibizumab and brolucizumab (no Fc) have minimal systemic exposure → safer in pregnancy and ROP.

---

🎤 How to Present Slide 12

"You might wonder — why can't these patients just take an injection in their arm? The answer is the blood-retinal barrier. To achieve therapeutic concentrations in the retina systemically, you'd need doses that cause significant cardiovascular side effects."

"Intravitreal injection solves this elegantly — you inject 0.05 mL directly into the vitreous, achieve micromolar concentrations right at the retina, and the systemic exposure is negligible. You're bypassing the BRB entirely because you're already inside the eye."

"The drug exits the eye anteriorly through aqueous outflow, or crosses the BRB into systemic circulation — and that's where molecular structure matters, as we'll see next."

---

---

🧠 MASTER MEMORY FRAMEWORK

HYPOXIA
   ↓
HIF-1α accumulates
   ↓
VEGF-A gene turns ON  ←── Primary therapeutic target
   ↓
VEGF-A165 secreted  ←── Most important isoform
   ↓
Binds VEGFR-2  ←── Main signaling receptor
   ↓
Ang-2 co-conspirator  ←── Faricimab's second target
   ↓
Leaky new vessels → SRF/IRF → Photoreceptor death
   ↓
BLOCK WITH: Anti-VEGF drugs given by IVI

---

🎤 GENERAL PRESENTATION TIPS FOR THIS PPT

1. Open strong: Don't read the title slide. Start with: "Retinal blindness from AMD and diabetes is driven by a single molecule — VEGF. Today I'm going to show you what it is, how it destroys vision, and how we stop it."
2. Use the cascade as your spine: Refer back to Slide 10 repeatedly. "Remember that HIF-VEGF cascade — this is where that drug acts."
3. For drug comparison tables: Don't read every cell. Pick 2-3 key comparators and say: "The most important comparison here is..."
4. For trial tables: Always say the same 4 things per trial — what was compared, what was found, what it changed in practice.
5. Pace: Slow down on Slides 7, 10, and 22. Speed through the detailed tables (Slides 13–14) by saying "you can read these, I'll highlight the key differences."
6. Closing the talk: End with Slide 49's take-home messages read directly — they are perfectly written as a summary. Then say: "Anti-VEGF has transformed blindness from retinal disease from inevitable to manageable — and we're now entering the era of longer intervals, gene therapy, and dual-mechanism drugs."

---